Introduction {#sec1}
============

Premature ejaculation (PE) in men is characterized by short ejaculatory latency during intercourse. PE can be lifelong (primary; present since first sexual experiences) or acquired (secondary; beginning later).[@bib1] The International Society for Sexual Medicine (ISSM; 2014) defines PE as a combination of (i) ejaculation usually occurring within approximately 1 minute of vaginal penetration (for lifelong PE) or a clinically significant decrease in latency time, often to no longer than approximately 3 minutes (for acquired PE); (ii) inability to delay ejaculation; and (iii) negative personal consequences such as distress, bother, frustration, and/or avoidance of sexual intimacy.[@bib1] PE also has been defined by the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (2013) as ejaculation usually occurring within approximately 1 minute of vaginal penetration and before the individual wishes it and causing clinically significant distress.[@bib2] Estimating the prevalence of PE is not straightforward because of the difficulty in defining what constitutes clinically relevant PE. Surveys have estimated the prevalence of self-reported early ejaculation as 20% to 30%[@bib3], [@bib4], [@bib5]; however, these estimates are likely to include men who have some concern about their ejaculatory function but do not meet the current diagnostic criteria for PE.[@bib6] It has been suggested that the prevalence of lifelong PE according to the ISSM and the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* definitions (with an ejaculatory latency of approximately 1 minute) is unlikely to exceed 4%.[@bib6] Men with PE are more likely to report lower levels of sexual functioning and satisfaction and higher levels of personal distress and interpersonal difficulty than men without PE.[@bib7] They also might rate their overall quality of life as lower than that of men without PE.[@bib7] In addition, their partner\'s satisfaction with the sexual relationship has been reported to decrease with increasing severity of the condition.[@bib8]

Management of PE can involve a range of interventions. These include systemic drug treatments such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, phosphodiesterase type 5 inhibitors, and analgesics and topical anesthetic creams and sprays that are applied directly to the penis shortly before intercourse.[@bib9], [@bib10] Behavioral therapies also can be useful.[@bib6], [@bib9], [@bib11], [@bib12] These can include psychosexual or relationship counseling for men and/or couples to address psychological and interpersonal issues that could be contributing to PE. Behavioral therapies also can include physical techniques to help men develop sexual skills to delay ejaculation and improve sexual self-confidence, such as the "stop-start" technique, "squeeze" technique, and sensate focus.[@bib6], [@bib9], [@bib11], [@bib12] There are sparse data on whether and for how long effectiveness is maintained after cessation of treatment (drug or behavioral) and whether repeat treatments are effective.

Many interventions currently used for PE are not approved for this use, and men might choose to self-treat, with several remedies being available through the internet. Some complementary and alternative medicines (CAMs) have been evaluated in randomized controlled trials (RCTs) for the management of PE. However, there are no existing systematic reviews evaluating CAMs for management of PE. Our aim was to systematically review the effectiveness, safety, and robustness of evidence for CAM therapies in the management of PE.

Methods {#sec2}
=======

Review Methods {#sec2.1}
--------------

This work was undertaken as part of a systematic review for the UK National Institute for Health Research Health Technology Assessment Programme, which assessed a wide range of interventions for management of PE.[@bib13] The review followed the general principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (<http://www.prisma-statement.org/>).[@bib14] The review protocol is available from the Health Technology Assessment Programme website (<http://www.nets.nihr.ac.uk/projects/hta/131201>) and is registered on the PROSPERO database (registration number CRD42013005289). The PRISMA checklist is provided in [Supplementary Appendix 3](#appsec1){ref-type="sec"}.

Definition of CAM {#sec2.2}
-----------------

CAM has been defined by the Cochrane Collaboration as "a broad domain of healing resources that encompasses all health systems, modalities, and practices and their accompanying theories and beliefs, other than those intrinsic to the politically dominant health system of a particular society or culture in a given historical period."[@bib15] In addition, many CAM therapies are based on a traditional model of health and well-being, and many (although not all) are designed to treat the whole patient as opposed to a specific condition, whereas some (although not all) involve the use of traditional or natural therapies. Therefore, CAM is defined in this study as therapies for PE that have typically not been provided within conventional Western health care systems and that appear on the list of CAM therapies collated by the Cochrane Collaboration.[@bib15]

Literature Searches {#sec2.3}
-------------------

The following databases were searched from inception to September 2015: Medline; Embase; Cumulative Index to Nursing and Allied Health Literature (CINAHL); the Cochrane Library including the Cochrane Systematic Reviews Database (CDSR), the Cochrane Controlled Trials Register (CCRT), the Database of Abstracts of Reviews of Effects (DARE), and the Health Technology Assessment database; the ISI Web of Science including the Science Citation Index and the Conference Proceedings Citation Index--Science. The Medline search strategy is provided in [Appendix 1](#appsec1){ref-type="sec"}. The search strategy was designed to identify any articles tagged with the Medical Subject Headings *ejaculation* or *premature ejaculation* plus articles whose title or abstract included one of the terms *premature, early,* or *rapid* within three words of *ejaculation* or *climax* or the term *ejaculation praecox/precox*. These were combined with search filters to identify RCTs, reviews, and guidelines. It should be noted that the search was undertaken as part of a wider project assessing different treatments for PE,[@bib13] and for this reason the search was not specific to complementary therapies. The US Food and Drug Administration website and the European Medicines Agency website also were searched. Existing systematic reviews and relevant studies also were checked for eligible studies.

Eligibility Criteria {#sec2.4}
--------------------

RCTs were eligible for inclusion if they compared CAM therapies for management of PE against placebo, waitlist, no treatment, or another therapy or assessed combination treatment. CAM is defined as therapies for PE that have typically not been provided within conventional Western health care systems and that appear on the list of CAM therapies collated by the Cochrane Collaboration.[@bib15]

Studies were included if they reported intravaginal ejaculatory latency time (IELT) and/or any of the following PE outcome measurements:▪Premature Ejaculation Profile (PEP)[@bib16]▪Index of Premature Ejaculation (IPE)[@bib17]▪Premature Ejaculation Diagnostic Tool (PEDT)[@bib18]▪Arabic Index of Premature Ejaculation (AIPE)[@bib19]▪Chinese Index of Premature Ejaculation--5 (CIPE-5)[@bib20]▪International Index of Erectile Function (IIEF)[@bib21]

Five of these measurements (PEP, IPE, PEDT, AIPE, and CIPE) were referenced in the update of the ISSM PE guidelines.[@bib6] Of these, PEP and IPE have been validated as tools to measure changes in PE outcomes,[@bib16], [@bib17] and CIPE also has been evaluated as a PE outcome measurement.[@bib20] The PEDT and AIPE have been validated as tools for diagnosing PE[@bib18], [@bib19] and have been used as outcome measurements in PE trials. In addition, the IIEF was validated for measuring changes in outcomes in erectile dysfunction, but some dimensions overlap with PE and have been used to measure outcomes in PE studies.[@bib21] Adverse effects also were summarized. Poorly defined outcomes, such as "percentage of patients showing improvement," were not included in this review.

Data Extraction and Synthesis {#sec2.5}
-----------------------------

One reviewer performed data extraction of each study; all numerical data were checked by a second reviewer. Results were presented as forest plots where data permitted, and meta-analyses were undertaken using RevMan software.[@bib22] Assessment of publication bias by visual inspection of funnel plots was planned when at least 10 RCT comparisons were available.[@bib23]

Assessment of Methodologic Quality of Studies {#sec2.6}
---------------------------------------------

Methodologic quality of included RCTs was assessed using the Cochrane Collaboration risk-of-bias assessment criteria.[@bib24] Completeness of outcome data was considered low risk if the percentage of randomized participants excluded from the primary analysis was smaller than 30%.[@bib25] Selective reporting was considered low risk if IELT or ejaculatory latency was reported and all outcomes referred to in the study methods were reported. Overall risk of bias for each study was classed as "low" or "high" if they were rated as such for each of three key domains: allocation concealment, blinding of outcome assessment, and completeness of outcome data; otherwise, overall risk of bias was classed as "unclear."

Results {#sec3}
=======

Quantity of Evidence {#sec3.1}
--------------------

The searches identified 2,455 citations (as part of a wider project assessing different treatments for PE). Fourteen studies were examined at the full-text stage. Ten RCTs evaluating a complementary therapy for PE were included in the review.[@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35] The PRISMA flowchart is presented in [Appendix 2](#appsec2){ref-type="sec"}. The four studies excluded at the full-text stage are described below, with reasons for exclusion.

Characteristics of Included Studies {#sec3.2}
-----------------------------------

Details of the included study characteristics are presented in [Table 1](#tbl1){ref-type="table"}; details include specific acupuncture points and herbal remedies used. Two studies (one in Turkey[@bib26] and one in China[@bib27]) assessed acupuncture provided daily for 4 weeks and twice weekly for 4 weeks, respectively. Each study used a set range of acupuncture points (with some overlap but some differences between studies). Five studies assessed a 2- to 8-week course of oral Chinese herbal medicine; all were conducted in China.[@bib28], [@bib29], [@bib30], [@bib31], [@bib32] One study conducted in India assessed Ayurvedic medicine (Indian herbal medicine) given for 2 months.[@bib33] Two Korean studies assessed four to five treatments with "severance secret" (SS) cream,[@bib34], [@bib35] an extract of nine natural products that is applied to the penis 1 hour before intercourse and washed off before intercourse. SS cream is believed to work by localized desensitizing effects to decrease penile hypersensitivity.[@bib34]

The number of analyzed participants was 50 to 200 for all studies, with the mean and median numbers being 98. Comparators included placebo (four studies),[@bib26], [@bib33], [@bib34], [@bib35] treatment as usual (one study),[@bib32] an SSRI (five studies),[@bib26], [@bib27], [@bib28], [@bib29], [@bib31] and/or a combination of CAM and drug treatment (three studies).[@bib28], [@bib30], [@bib31] Nine of the 10 studies assessed IELT[@bib26], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35]: five by stopwatch,[@bib26], [@bib28], [@bib29], [@bib34], [@bib35] one by questionnaire,[@bib32] and three did not report the method of IELT assessment.[@bib30], [@bib31], [@bib33] Additional outcome measurements reported included the PEDT (three studies)[@bib26], [@bib28], [@bib29], the CIPE-5 (two studies)[@bib27], [@bib32], and the IIEF (one study).[@bib31]

Three studies included men with lifelong PE,[@bib30], [@bib34], [@bib35] one included men with only acquired PE,[@bib28] four included men with lifelong PE and men with acquired PE,[@bib26], [@bib29], [@bib32], [@bib33] and two did not report this information.[@bib27], [@bib31] Participants had an IELT no longer than 1 minute (most or all the time) in two studies,[@bib28], [@bib33] an IELT no longer than 2 minutes (most or all the time) in five studies,[@bib26], [@bib29], [@bib30], [@bib31], [@bib32] an IELT no longer than 3 minutes in two studies,[@bib34], [@bib35] and IELT inclusion criteria were not reported in one study.[@bib27] In four studies, patient or partner satisfaction also had to be below 30% or below 50%.[@bib32], [@bib33], [@bib34], [@bib35] In some studies, the inclusion criteria were not consistent with the ISSM definition of PE. For example, one study of Chinese herbal medicine recruited men with acquired PE, but they had to have an IELT shorter than 1 minute in at least 50% of attempts[@bib28] (whereas the ISSM widens the definition of acquired PE to IELT ≤ 3 minutes[@bib36]). Also, two studies of SS cream stated that participants had lifelong PE but were required only to have an IELT shorter than 3 minutes (plus patient or partner satisfaction below 30% or 50%)[@bib34], [@bib35] rather than no longer than 1 minute according to the ISSM definition of lifelong PE.[@bib6]

Studies Excluded at Full-Text Stage {#sec3.3}
-----------------------------------

Four studies were excluded at the full-text stage. Two studies of Chinese medicine were excluded because they did not report on IELT or any validated or widely used PE outcome measurement.[@bib36], [@bib37] Two studies assessing a combination of yoga and pelvic floor exercises were excluded; one was not randomized (patients self-selected to the intervention or control group)[@bib38] and the other did not report on IELT or any validated or widely used PE outcome measurement.[@bib39]

Risk of Bias in Included Studies {#sec3.4}
--------------------------------

The risk of bias within included studies is presented in [Table 2](#tbl2){ref-type="table"}. Five studies reported the method of randomization,[@bib26], [@bib28], [@bib29], [@bib32], [@bib35] whereas the other five did not report the method but did state that the study was randomized. Allocation concealment was unclear in all studies. Blinding of participants and personnel was reported as being undertaken in five studies.[@bib26], [@bib29], [@bib33], [@bib34], [@bib35] Blinding of outcome assessment was unclear in all studies except one,[@bib35] which reported that this was blinded. All studies except one[@bib35] were considered at low risk of bias for completeness of outcome data, with eight studies including at least 90% of randomized patients in the primary analysis and the two studies of SS cream including 85%[@bib34] and 68%,[@bib35] respectively. All studies scored a low risk for selective reporting except for one that did not report on IELT.[@bib27] Of the nine studies reporting on IELT, this was measured by stopwatch in five studies,[@bib26], [@bib28], [@bib29], [@bib34], [@bib35] by questionnaire in one study,[@bib32] and the method of IELT assessment was not reported in three studies.[@bib30], [@bib31], [@bib33] In summary, all 10 studies were classed as having an overall unclear risk of bias because of unclear reporting of allocation concealment (all 10 studies) and unclear blinding of participants and personnel (five studies).

Assessment of Effectiveness and Safety {#sec3.5}
--------------------------------------

Effectiveness results are presented in [Table 3](#tbl3){ref-type="table"} and adverse effects are presented in [Table 4](#tbl4){ref-type="table"}. Further details of effectiveness (including results data per study group) are presented in [Table 5](#tbl5){ref-type="table"}.

### Acupuncture {#sec3.5.1}

Two RCTs (one in Turkey[@bib26] and one in China[@bib27]) assessed acupuncture provided daily for 4 weeks and twice weekly for 4 weeks, respectively. Each study used a standardized range of acupuncture points for all patients. There was some overlap, but also some differences, between the acupuncture points used in the two studies ([Table 1](#tbl1){ref-type="table"}). There were no studies of individualized acupuncture treatment (where different points are used per patient based on clinical examination).

One study compared acupuncture against sham acupuncture (N analyzed = 60) and reported a small but significant improvement in stopwatch-measured IELT for acupuncture over sham (mean difference (MD) = 0.55 minute, *P* = .001) and a significant improvement in PEDT score (*P* = .001; [Table 3](#tbl3){ref-type="table"}).[@bib26] These two studies showed mixed results when comparing acupuncture against drug treatment with an SSRI (paroxetine or citalopram, each given daily for 4 weeks),[@bib26], [@bib27] with IELT favoring drug treatment in the one study reporting this (N = 60; MD = −0.28, *P* = .001),[@bib26] a PEDT score showing no significant difference (*P* value not reported),[@bib26] and a CIPE-5 score favoring acupuncture in the other study (N = 111; *P* = .05).[@bib27] One study reported that no adverse effects were observed (although there was no formal evaluation of these),[@bib26] and the other study did not report adverse effect data ([Table 4](#tbl4){ref-type="table"}).[@bib27]

In summary, the available data indicate that acupuncture might be slightly more effective than placebo (sham) in treating PE, although this is based on only one study of unclear quality.

### Chinese Herbal Medicine {#sec3.5.2}

Five RCTs (all conducted in China) assessed a 2- to 8-week course of oral Chinese herbal medicine.[@bib28], [@bib29], [@bib30], [@bib31], [@bib32] Each study used the same herbal medicine(s) for all patients. There were no studies of individualized Chinese medicine (where different herbs are used per patient based on clinical examination). The specific Chinese medicines used differed among studies. One study used *Qilin* pills (a combination of herbs; [Table 1](#tbl1){ref-type="table"}) at a dose of 6 g twice daily[@bib28]; one used mycelium of *Cordyceps sinensis C4*[@bib29]; two used Yimusake (one at 50 mg/d[@bib30] and one at 1.5 g/d[@bib31]); and one used *Uighur* twice daily.[@bib32]

Results for Chinese medicine are presented in [Table 3](#tbl3){ref-type="table"} and [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}. One study favored Chinese medicine (*Uighur*) over treatment as usual (N analyzed = 68),[@bib32] reporting significant differences in IELT measured by questionnaire (MD = 1.57 minutes, 95% CI = 1.11--2.03, *P* \< .00001) and CIPE-5 score (*P* \< .00001; [Table 3](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Three studies compared Chinese medicine against drug treatment with an SSRI (fluoxetine or sertraline, each given daily for 4--8 weeks).[@bib28], [@bib29], [@bib31] Of these, two studies significantly favored SSRIs over Chinese medicine (mycelium of *Cordyceps sinensis C4* or *Yimusake*) for IELT (one measured by stopwatch) and PEDT and IIEF scores,[@bib29], [@bib31] whereas the third study showed no significant difference in stopwatch-measured IELT or PEDT score between the SSRI and Chinese medicine (*Qilin* pills; [Table 3](#tbl3){ref-type="table"}).[@bib28] A meta-analysis of IELT across all three studies significantly favored drug treatment with SSRIs (total N = 355; pooled MD = 1.01 minutes, 95% CI = 0.18--1.84, *P* = .02; [Figure 1](#fig1){ref-type="fig"}), with a high level of heterogeneity (I^2^ = 86%, *P* = .0007).

Two studies compared Chinese medicine (*Qilin* pills or *Yimusake*) plus SSRI (fluoxetine or sertraline) against SSRI alone.[@bib28], [@bib31] These studies (total N = 155) significantly favored combination treatment over SSRI alone for IELT (one measured by stopwatch; pooled MD = 1.92 minutes, 95% CI = 1.51--2.32, *P* \< .00001) with low heterogeneity (I^2^ = 0%, *P* = .82); PEDT and IIEF scores also favored combination treatment (*P* \< .001 for the two comparisons; [Table 3](#tbl3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}).

The same two studies compared Chinese medicine (*Qilin* pills or *Yimusake*) plus SSRI (fluoxetine or sertraline) against Chinese medicine alone.[@bib28], [@bib31] These studies (total N = 156) significantly favored combination treatment over Chinese medicine alone for IELT (one measured by stopwatch; pooled MD = 2.52, 95% CI = 2.13--2.91, *P* \< .00001) with low heterogeneity (I^2^ = 0%, *P* = .76); PEDT and IIEF scores also favored combination treatment (*P* \< .0001 for all comparisons). Results favoring combination treatment over drug or Chinese medicine alone (for IELT and PEDT) remained significant 1 month after treatment ended in the one study reporting this.[@bib28] A third study (N = 68) comparing Chinese medicine (*Yimusake*) plus a serotonin antagonist and reuptake inhibitor (trazodone) against Chinese medicine alone[@bib30] showed no significant difference in IELT (measurement method not reported; MD = 0.08, 95% CI = −0.19 to 0.35, *P* = .56; [Table 3](#tbl3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}).

Four of five studies reported data on adverse effects ([Table 4](#tbl4){ref-type="table"}).[@bib28], [@bib29], [@bib30], [@bib31] For patients receiving Chinese medicine alone, two studies reported that no adverse effects were observed (one of *Qilin* pills 6 g twice daily[@bib28] and one of *Yimusake* 50 mg/d[@bib30]). One study reported adverse effects in 12% of patients receiving mycelium of *Cordyceps sinensis C4* (including gastrointestinal discomfort, dizziness, and decreased libido),[@bib29] whereas one study reported that the number of adverse effects did not differ significantly among Chinese medicine alone (*Yimusake* 1.5 g/d), fluoxetine alone, and combination treatment.[@bib31]

In summary, across studies of Chinese medicine, one study favored Chinese medicine over treatment as usual.[@bib32] A meta-analysis of three studies favored SSRI treatment over Chinese medicine.[@bib28], [@bib29], [@bib31] Two studies favored Chinese medicine plus SSRIs over SSRIs alone or Chinese medicine alone.[@bib28], [@bib31]

### Ayurvedic Medicine {#sec3.5.3}

One RCT conducted in India (N analyzed = 50) assessed a 2-month course of Ayurvedic medicine (Indian herbal medicine) plus psychological counseling compared with placebo plus psychological counseling.[@bib33] Ayurvedic medicine showed a small but significant improvement in IELT (measurement method not reported; MD = 0.80 minute, 95% CI = 0.32--1.28, *P* = .001; [Table 3](#tbl3){ref-type="table"}). Adverse effects were not reported.

### SS Cream {#sec3.5.4}

Two crossover RCTs conducted in Korea compared SS cream against placebo.[@bib34], [@bib35] These two RCTs showed significant effects on stopwatch-measured IELT (total N = 156; pooled MD = 8.60 minutes, 95% CI = 7.09--10.10, *P* \< .001) with low heterogeneity (I^2^ = 0%, *P* = .84; [Table 3](#tbl3){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}). The two studies used a single-group crossover design in which each patient received four or five applications of SS cream and one of placebo. One study[@bib35] used different doses of SS cream; only the results for the maximum dose (0.2 g) are presented. Patients might have had less severe PE than those in some other studies because the inclusion criterion was an IELT shorter than 3 minutes (combined with low partner satisfaction in one study). Adverse effects included a mild burning sensation in 15% of patients (the two studies) and mild pain in 0.04% to 4% of patients ([Table 4](#tbl4){ref-type="table"}).

Summary {#sec3.6}
-------

The included studies evaluated the effectiveness of acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine, and topical SS cream in improving IELT and other outcomes. Overall risk of bias was unclear in all studies because of unclear allocation concealment and/or blinding. Studies were clinically heterogeneous and stopwatch-measured IELT was reported in only 5 of 10 studies. Acupuncture increased IELT over placebo (one study; MD = 0.55 minute, *P* = .001). Ayurvedic herbal medicine increased IELT over placebo (one study; MD = 0.80 minute, *P* = .001). Topical SS cream improved IELT over placebo in two crossover studies (MD = 8.60 minutes, *P* \< .001), although inclusion criteria were broad (IELT \< 3 minutes), and there were mild irritant effects in some patients. SSRIs were more effective on IELT than Chinese herbal medicine (three studies; MD = 1.01 minutes, *P* = .02). However, combination treatment with Chinese medicine plus SSRIs improved IELT over SSRIs alone (two studies; MD = 1.92 minutes, *P* \< .00001) or Chinese medicine alone (two studies; MD = 2.52 minutes, *P* \< .00001). Adverse effects were not consistently assessed but where reported were generally mild. There were sparse data on the potential for drug interactions.

Discussion {#sec4}
==========

Our systematic review is (to our knowledge) the first to evaluate CAM for PE. All studies were classed as having an overall unclear risk of bias because of limited reporting. Blinding of participants and personnel was difficult in many studies because of the nature of the interventions, although a few studies used placebo. However, because most studies included an active control group (eg, drug treatment), any placebo effect might be expected to occur in the two groups. It was not possible to conduct a formal test for publication bias or produce funnel plots because of the small number of studies in each analysis. However, all but three studies were conducted in single centers,[@bib31], [@bib32], [@bib34] and single-center trials tend to show larger treatment effects than multicenter trials,[@bib40] possibly because of a lower likelihood of publication if the result is negative (publication bias), lower methodologic quality, and/or more selected patients.[@bib23]

Regarding outcomes, 9 of 10 included studies assessed IELT but only five reported on stopwatch-measured IELT. Because IELT tends to be positively skewed, it has been suggested that studies should report geometric (rather than arithmetic) mean IELT.[@bib41] None of the included studies reported geometric mean IELT, although two studies used the Mann-Whitney U-test for between-group differences because of non-normal distribution of data.[@bib26], [@bib29] Additional outcomes included PEDT, CIPE-5, and IIEF scores. Although it is important that clinical studies assess non-IELT outcomes in addition to IELT,[@bib42] there is a need for greater agreement on which measurements are most robust. Duration of the interventions was 2 to 8 weeks in all studies (or one to five applications for SS cream). Only one study (of Chinese medicine) provided follow-up data beyond the end of treatment and reported that differences remained significant 1 month after treatment ended. For most interventions, it was not clear how long the effects might last or whether repeat treatments were effective. This is an issue for all PE treatments.

An interesting point relates to the nature of CAM therapies. In clinical practice, many CAM therapies involve a holistic approach based on the patient\'s overall pattern of health. It can be difficult to determine how much of the treatment effect is due to the specific treatment (acupuncture, herbs) and how much is due to the patient-therapist interaction and other aspects (eg, lifestyle advice). Some researchers believe the patient-therapist interaction and other aspects of treatment should be controlled for, whereas others argue that they are a valid element of treatment.[@bib43], [@bib44], [@bib45] A related issue is whether CAM therapies are individualized to the patient (eg, in clinical practice, two patients with PE might receive different herbal remedies or acupuncture points depending on their overall symptom picture).[@bib43], [@bib44] All studies included in this review used a standardized treatment across patients within a study (same set of acupuncture points or same Chinese herbal preparation), although treatments varied among studies. Although standardized treatment protocols increase reproducibility, effectiveness of CAM therapies could be compromised by this approach.

None of the included therapies are commonly provided for PE by Western government health services. This has implications for access and use of these therapies. Acupuncture, Chinese medicine, and Ayurvedic medicine might be available from private practitioners, whereas SS cream currently has limited availability outside Korea. Pragmatically, because there are so many CAM therapies available, it seems unlikely that they will all undergo further evaluation in large-scale studies. Therefore, it might be reasonable to summarize that the CAM therapies reviewed here have some (although limited) evidence for effectiveness in treating PE, and that they might provide another option for patients who favor a mind-body approach or who wish to avoid long-term pharmacologic treatment. It would need to be borne in mind that the effectiveness evidence is not conclusive, and care would need to be taken to monitor for adverse effects and to consider the potential for herb-drug interactions.

Regarding further research, it would be useful to see further RCTs in a Western setting for any of the included treatments, because all had some (limited) evidence of effectiveness in PE. It would be useful to conduct comparisons against placebo, no treatment, existing therapies (drug or behavioral treatment), and combination treatment. To increase consistency and facilitate meta-analyses, future studies should recruit men meeting the ISSM definition of PE, measure stopwatch-assessed IELT, and report additional outcomes using validated instruments. Additional areas for further study could include optimum duration of therapy and how effects might best be maintained in the long term.

Conclusions {#sec5}
===========

There is preliminary evidence for effectiveness of some CAM therapies in PE. However, results are based on clinically heterogeneous, mostly single-center studies of unclear quality. Acupuncture, Ayurvedic medicine, and SS cream improved IELT and other outcomes over placebo based on limited data. Chinese herbal medicine was not as effective as SSRIs, whereas combination treatment with Chinese medicine plus SSRIs improved outcomes over either therapy alone. Adverse effects were not consistently assessed, although where reported they were generally mild, and there were sparse data on the potential for drug interactions. Further well-conducted RCTs of all treatments would be valuable.
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Appendix 1. Medline search strategy {#appsec1}
===================================

Medline search strategy1.exp Ejaculation/2.exp Premature Ejaculation/3.(premature\$ adj3 ejaculat\$).ti,ab.4.(early adj3 ejaculat\$).ti,ab.5.(rapid adj3 ejaculat\$).ti,ab.6.(rapid adj3 climax\$).ti,ab.7.(premature\$ adj3 climax\$).ti,ab.8.(ejaculat\$ adj3 pr?ecox).ti,ab.9.or/1-8.Filter 1: Randomized Controlled Trials10.Randomized Controlled Trials as Topic/11.randomized controlled trial/12.Random Allocation/13.Double Blind Method/14.Single Blind Method/15.clinical trial/16.clinical trial, phase i.pt.17.clinical trial, phase ii.pt.18.clinical trial, phase iii.pt.19.clinical trial, phase iv.pt.20.controlled clinical trial.pt.21.randomized controlled trial.pt.22.multicenter study.pt.23.clinical trial.pt.24.exp Clinical Trials as topic/25.or/10-2426.(clinical adj trial\$).tw.27.((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.28.PLACEBOS/29.placebo\$.tw.30.randomly allocated.tw.31.(allocated adj2 random\$).tw.32.26 or 27 or 28 or 29 or 30 or 3133.25 or 3234.case report.tw.35.letter/36.historical article/37.34 or 35 or 3638.33 not 37Filter 2: Reviews10.review.ab.11.review.pt.12.meta-analysis.ab.13.meta-analysis.pt.14.meta-analysis.ti.15.or/10-1416.letter.pt.17.comment.pt.18.editorial.pt.19.or/16-1820.15 not 19Filter 3: Guidelines10.guideline.pt.11.practice guideline.pt.12.exp Guideline/13.health planning guidelines/14.10 or 11 or 12 or 13

Supplementary data {#appsec2}
==================

Supplementary Appendix 2Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart. RCT = randomized controlled trial.Supplementary Appendix 3Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.
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![Intravaginal ejaculatory latency time for Chinese medicine (CM).](gr1){#fig1}

![Intravaginal ejaculatory latency time for Chinese medicine (CM) combined with drug treatment. fluox = fluoxetine; SARI = serotonin antagonist and reuptake inhibitor (trazodone); sert = sertraline; SSRI = selective serotonin reuptake inhibitor; trazo = trazodone.](gr2){#fig2}

![Intravaginal ejaculatory latency time for secret severance (SS) cream.](gr3){#fig3}

###### 

Characteristics of included studies

  Study; country; center, n                         Duration (n), IELT assessment                                Treatments and comparators                                                                      CAM treatment details                                                                                                                                                                                                                                                                                                                                                                                                                       PE definition                                                                                      Lifelong and acquired
  ------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- --------------------------------
  Acupuncture                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Sunay et al,[@bib26] 2011; Turkey; 1             4 wk (n = 90, a = 90), stopwatch                             Acupuncture 2×/wk; paroxetine 20 mg/d; sham acupuncture 2× weekly                               Acupuncture 2×/wk using points Zusanli (ST 36), Hegu (LI 4), Taixi (KI 3), Taichong (LR 3), Yintang (EX-HN 3), Zhongji (CV 3)                                                                                                                                                                                                                                                                                                               IELT ≤ 2 min in \>70% of attempts                                                                  Lifelong 66%, acquired 34%
   Chen,[@bib27] 2009; China; 1                     4 wk (n = 111, a = 111), method NR                           Acupuncture daily; citalopram 20 mg/d                                                           Acupuncture: 2 groups of acupoints on alternate days: day 1, Xinshu (BL 15), Ganshu (BL 18), Pishu (BL 20), Shenshu (BL 23); day 2, Guanyuan (CV 4), Zhongji (CV 3), Sanyinjiao (SP 6), Taixi (KI 3), Taichong (LR 3)                                                                                                                                                                                                                       NR                                                                                                 NR
  Chinese herbal medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Li and Lu,[@bib28] 2015; China; 1                4 wk (n = 120, a = 119), stopwatch                           Chinese medicine (*Qilin* pills) 6 g 2×/d; sertraline 50 mg/d; Chinese medicine + sertraline    Chinese medicine (*Qilin* pills) containing Chinese raspberry (*fu pen zi*), horny goat weed (*yin yang huo*), *Polygonum multiflorum* (*he shou wu*), *Herba ecliptae* (*mo han lian*), *Cynomonium* (*suo yang*), *Astralagus* (*huang qi*), Chinese yam (*shan yao*), immature tangerine peel (*qing pi*), mulberry fruit spike (*sang shen*), turmeric tuber (*yu jin*), Chinese red sage (*dan shen*), white peony root (*bai shao*)   IELT \< 1 min in \>50% of attempts + TCM definition of "secondary non-consolidated kidney qi PE"   Acquired (≥3 mo)
   Xu et al,[@bib29] 2014; China; 1                 8 wk (n = 218, a = 200), stopwatch                           Chinese medicine (mycelium of *Cordyceps sinensis C4*); sertraline 50 mg/d                      Chinese medicine (mycelium of *Cordyceps sinensis C4*)                                                                                                                                                                                                                                                                                                                                                                                      IELT ≤ 2 min in ≥75% of attempts                                                                   Acquired and lifelong (n = NR)
   Xu et al,[@bib30] 2012; China; 1                 4 wk (n = 68, a = 68), method NR                             Chinese medicine (*Yimusake* 50 mg/d); Chinese medicine + trazodone 50 mg/d                     Chinese medicine (*Yimusake* 50 mg/d)                                                                                                                                                                                                                                                                                                                                                                                                       IELT \< 2 min                                                                                      Lifelong
   Sun et al,[@bib31] 2010; China; 2                4 wk (n = 114, a = 114), method NR                           Chinese medicine (*Yimusake* 1.5 g/d); fluoxetine 20 mg/d; Chinese medicine + fluoxetine        Chinese medicine (*Yimusake* 1.5 g/d)                                                                                                                                                                                                                                                                                                                                                                                                       IELT \< 2 min                                                                                      NR
   Song et al,[@bib32] 2007; China; 2               15 d (n = 68, a = 68), questionnaire                         Chinese medicine (*Uighur*) 2×/d; treatment as usual                                            Chinese medicine (*Uighur*) 2×/d                                                                                                                                                                                                                                                                                                                                                                                                            IELT ≤ 2 min, partner satisfaction \< 50%                                                          Acquired and lifelong (n = NR)
  Ayurvedic herbal medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Kulkarni and Chandola,[@bib33] 2013; India; 1    2 mo (n = 55, a = 50), method NR                             Ayurvedic herbal medicine 2×/d + psychological counseling; placebo + psychological counseling   Ayurvedic herbal medicine 2×/d: *Stambhanakaraka Yoga* containing *Tulsi beeja* (*Occimum santum* Linn), *Akarakarabha* (*Anacyclus pyrethrum* Linn), *Mishri* (sugar)                                                                                                                                                                                                                                                                      IELT ≤ 1 min, partner satisfaction \< 50%                                                          Acquired and lifelong (n = NR)
  Topical herbal SS cream                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Choi et al,[@bib34] 2000; Korea; 3 (crossover)   5 applications (n = 125, a = 106), stopwatch                 SS cream (0.20 g applied 1 h before intercourse); placebo                                       SS cream: extracts of 9 natural products applied to glans penis 1 h before intercourse and then washed off (*Ginseng radix alba, Angelicae gigantis radix, Cistanches herba, Zanthoxyli fructus, Torlidis semen, Asiasari radix, Caryophylli flos, Cinnamomi cortex, Bufonis venenum*)                                                                                                                                                      IELT \< 3 min AND patient and partner satisfaction \<30%                                           Lifelong
   Choi et al,[@bib35] 1999; Korea; 1 (crossover)   4 applications (1 of each dose; n = 73, a = 50), stopwatch   SS cream (0.05, 0.10, 0.15, or 0.20 g applied 1 h before intercourse); placebo                  SS cream: extracts of 9 natural products as above                                                                                                                                                                                                                                                                                                                                                                                           IELT \< 3 min and/or patient satisfaction \< 50%                                                   Lifelong

a = analyzed number; CAM = complementary and alternative medicine; IELT = intravaginal ejaculatory latency time; n = randomized number; NR = not reported; PE = premature ejaculation; SS = secret severance; TCM = traditional Chinese medicine.

###### 

Risk of bias in included studies

  RCT; country                                  Risk of bias                                                                                       
  --------------------------------------------- -------------- --------- ------------------------ --------- --------------------- ---------------- ---------
  Acupuncture                                                                                                                                      
   Sunay et al,[@bib26] 2011; Turkey            Low            Unclear   Low (partial blinding)   Unclear   Low (90/90, 100%)     Low              Unclear
   Chen,[@bib27] 2009; China                    Unclear        Unclear   High                     Unclear   Low (111/111, 100%)   High (no IELT)   Unclear
  Chinese herbal medicine                                                                                                                          
   Li and Lu,[@bib28] 2015; China               Low            Unclear   High                     Unclear   Low (119/120, 99%)    Low              Unclear
   Xu et al,[@bib29] 2014; China                Low            Unclear   Low                      Unclear   Low (200/218, 92%)    Low              Unclear
   Xu et al,[@bib30] 2012; China                Unclear        Unclear   High                     Unclear   Low (68/68, 100%)     Low              Unclear
   Sun et al,[@bib31] 2010; China               Unclear        Unclear   High                     Unclear   Low (114/114, 100%)   Low              Unclear
   Song et al,[@bib32] 2007; China              Low            Unclear   High                     Unclear   Low (68/68, 100%)     Low              Unclear
  Ayurvedic herbal medicine                                                                                                                        
   Kulkarni and Chandola,[@bib33] 2013; India   Unclear        Unclear   Low                      Unclear   Low (50/55, 91%)      Low              Unclear
  Topical herbal SS cream                                                                                                                          
   Choi et al,[@bib34] 2000; Korea              Unclear        Unclear   Low                      Unclear   Low (106/125, 85%)    Low              Unclear
   Choi et al,[@bib35] 1999; Korea              Low            Unclear   Low                      Low       High (50/73, 68%)     Low              Unclear

IELT = intravaginal ejaculatory latency time; SS = secret severance.

Completeness of outcome data was classed as low risk if fewer than 30% randomized participants were excluded from the primary analysis.

Selective reporting was classified as low risk if IELT or ejaculatory latency was reported and all outcomes referred to in study methods were reported.

Overall risk of bias was classified as low or high if rated as such for each of three key domains: allocation concealment, blinding of outcome assessment, and completeness of outcome data; otherwise, overall risk of bias was classed as unclear.

###### 

Effectiveness results

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies, n                             Treatment                                     Comparator                Duration   Reference               Outcome                 Participants, n   MD (95% CI), *P* value                Favors
  -------------------------------------- --------------------------------------------- ------------------------- ---------- ----------------------- ----------------------- ----------------- ------------------------------------- ---------------------------------------------------
  Acu vs placebo                                                                                                                                                                                                                    

   1                                     Acu 2x/wk                                     Sham acu                  4 wk       Sunay 2011[@bib26]      IELT (stopwatch)\       60\               MD = 0.55 (NR), .001\                 Acu over sham\
                                                                                                                                                    PEDT                    60                MD = NR (NR), .001                    Acu over sham

  Acu vs drug                                                                                                                                                                                                                       

   2                                     Acu 2x/wk                                     Paroxetine 20 mg/d        4 wk       Sunay 2011[@bib26]      IELT (stopwatch)\       60\               MD = −0.28 (NR), .001\                Drug over acu\
                                                                                                                                                    PEDT                    60                MD = NR (NR), NS                      Not sig (acu vs drug)

                                         Acu daily                                     Citalopram 20 mg/d        4 wk       Chen 2009[@bib27]       CIPE-5                  111               MD = 1.44 (0.02 to 2.86), .05         Acu over drug

  CM vs TAU                                                                                                                                                                                                                         

   1                                     CM (*Uighur* 2x/d)                            TAU                       15 d       Song 2007[@bib32]       IELT (questionnaire)\   68\               MD = 1.57 (1.11 to 2.03), .00001\     CM over TAU\
                                                                                                                                                    CIPE-5                  68                MD = 4.95 (3.34 to 6.56), .00001      CM over TAU

  CM vs drug                                                                                                                                                                                                                        

   3                                     CM (*Qilin* pills 6 g 2x/d)                   Sertraline 50 mg/d        4 wk       Li 2015[@bib28]         IELT (stopwatch)\       79\               MD = −0.64 (−1.58 to 0.30), .18\      Not sig (drug vs CM)\
                                                                                                                                                    PEDT                    79                MD = −0.20 (−0.97 to 0.57), .61       Not sig (drug vs CM)

                                         CM (*mycelium of cordyceps sinensis C4*)      Sertraline 50 mg/d        8 wk       Xu 2014[@bib29]         IELT (stopwatch)\       200\              MD = −1.70 (−2.12 to −1.28), \<.01\   Drug over CM\
                                                                                                                                                    PEDT                    200               MD = −3.8 (−5.01 to −2.59), \<.01     Drug over CM

                                         CM (*Yimusake* 1.5 g/d)                       Fluoxetine 20 mg/d        4 wk       Sun 2010[@bib31]        IELT (method NR)\       76\               MD = −0.60 (−1.01 to −0.19), .004\    Drug over CM\
                                                                                                                                                    Satisfaction (IIEF)     76                MD = −0.90 (−1.43 to −0.37), .0009    Drug over CM

  CM + drug vs drug alone                                                                                                                                                                                                           

   2                                     CM (*Qilin*) + sertraline                     Sertraline 50 mg/d        4 wk       Li 2015[@bib28]         IELT (stopwatch)\       79\               MD = 2.05 (0.83 to 3.27), .001\       Combined over drug\
                                                                                                                                                    PEDT                    79                MD = 1.10 (0.46 to 1.74), .0008       Combined over drug

                                         CM (*Yimusake*) + fluoxetine                  Fluoxetine 20 mg/d        4 wk       Sun 2010[@bib31]        IELT (method NR)\       76\               MD = 1.90 (1.47 to 2.33), \<.00001\   Combined over drug\
                                                                                                                                                    Satisfaction (IIEF)     76                MD = 3.00 (2.46 to 3.54), \<.00001    Combined over drug

  CM + drug vs CM alone                                                                                                                                                                                                             

   3                                     CM (*Qilin*) + sertraline                     CM (*Qilin* 6 g 2x/d)     4 wk       Li 2015[@bib28]         IELT (stopwatch)\       80\               MD = 2.69 (1.57 to 3.81), \<.00001\   Combined over CM\
                                                                                                                                                    PEDT                    80                MD = 1.30 (0.63 to 1.97), .0001       Combined over CM

                                         CM (*Yimusake*) + fluoxetine                  CM (*Yimusake* 1.5 g/d)   4 wk       Sun 2010[@bib31]        IELT (method NR)\       76\               MD = 2.50 (2.08 to 2.92), \<.00001\   Combined over CM\
                                                                                                                                                    Satisfaction (IIEF)     76                MD = 3.90 (3.32 to 4.48), \<.00001    Combined over CM

                                         CM (*Yimusake* 50 mg/d) + trazodone 50 mg/d   CM (*Yimusake* 50 mg/d)   4 wk       Xu 2012[@bib30]         IELT (method NR)        68                MD = 0.08 (−0.19 to 0.35), .56        Not sig (combined vs. CM)

  Ayurvedic herbal medicine vs placebo                                                                                                                                                                                              

   1                                     Ayurvedic med + counselling                   Placebo + counselling     2 mo       Kulkarni 2013[@bib33]   IELT (method NR)        50                MD = 0.80 (0.32 to 1.28), .001        Ayurveda + counselling over placebo + counselling

  Topical herbal SS cream vs placebo                                                                                                                                                                                                

   2                                     SS cream (0.2 g/h prior)                      Placebo (crossover)       5 app      Choi 2000[@bib34]       IELT (stopwatch)        106               MD = 8.47 (6.52 to 10.42), \<.001     SS cream over placebo

                                         SS cream (0.2 g/h prior)                      Placebo (crossover)       1 app      Choi 1999[@bib35]       IELT (stopwatch)        50                MD = 8.79 (6.41 to 11.17), \<.001     SS cream over placebo
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Acu = acupuncture; app = applications; CI = confidence interval; CIPE = Chinese Index of Premature Ejaculation; CM = Chinese medicine; IELT = intra-vaginal ejaculatory latency time; IIEF = International Index of Erectile Function; MD = mean difference; NR = not reported; PEDT = Premature Ejaculation Diagnostic Tool; TAU = treatment as usual.

###### 

Adverse effects

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, country, duration (n)                                          Treatments                                                              AEs
  --------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Acupuncture                                                                                                                                   

   Sunay et al,[@bib26] 2011, Turkey, 4 wk (n = 90, a = 90)             Acupuncture 2×/wk, paroxetine 20 mg/d, sham acupuncture 2×/wk           No AEs observed (although no formal evaluation of AEs)

   Chen,[@bib27] 2009, China, 4 wk (n = 111, a = 111)                   Acupuncture daily, citalopram 20 mg/d                                   NR

  Chinese herbal medicine                                                                                                                       

   Li and Lu,[@bib28] 2015, China, 4 wk (n = 120, a = 119)              CM (*Qilin* pills 6 g 2×/d), sertraline 50 mg/d, CM + sertraline        CM: no AEs reported\
                                                                                                                                                Sertraline: mild transient AEs (gastrointestinal discomfort in 3, headache and dizziness in 2); 1 patient receiving only sertraline discontinued because of erectile dysfunction

   Xu et al,[@bib29] 2014, China, 8 wk (n = 218, a = 200)               CM (mycelium of *Cordyceps sinensis C4*), sertraline 50 mg/d            CM: 7/61 (11.5%) developed mild AEs (dizziness in 2, decreased libido in 1, gastrointestinal discomfort in 4), no discontinuations\
                                                                                                                                                Sertraline: 52/157 (33.1) developed mild AEs (dizziness in 30, decreased libido in 12, other); 3/157 (1.9%) discontinued because of severe dizziness

   Xu et al,[@bib30] 2012, China, 4 wk (n = 68, a = 68)                 CM (*Yimusake* 50 mg/d), CM + trazodone 50 mg/d                         CM alone: no AEs\
                                                                                                                                                CM + trazodone: minor AEs (headache in 2, dry mouth in 1, constipation in 1)

   Sun et al,[@bib31] 2010, China, 4 wk (n = 114, a = 114)              CM (*Yimusake* 1.5 g/d), fluoxetine 20 mg/d, CM + fluoxetine            Number of AEs with CM + fluoxetine were not significantly different from CM or fluoxetine alone (included nausea, dizziness, headache, flushing, somnolence)

   Song et al,[@bib32] 2007, China, 15 d (n = 68, a = 68)               CM (*Uighur*) 2×/d, treatment as usual                                  NR

  Ayurvedic herbal medicine                                                                                                                     

   Kulkarni and Chandola,[@bib33] 2013, India, 2 mo (n = 55, a = 50)    Ayurvedic medicine + counseling, placebo + counseling                   NR

  Topical herbal SS cream                                                                                                                       

   Choi et al,[@bib34] 2000, Korea, 6 applications (n = 125, a = 106)   SS cream (0.20 g 1 h before intercourse), placebo                       SS cream: mild burning sensation in 15% of applications, mild pain in 4% of applications, effects resolved \< 1 h

   Choi et al,[@bib35] 1999, Korea, 4 applications (n = 73, a = 50)     SS cream (0.05, 0.10, 0.15 or 0.20 g 1 h before intercourse), placebo   SS cream: mild burning sensation in 15% of applications, mild pain in 0.04% of applications
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a = number analyzed; AE = adverse effect; CM = Chinese medicine; n = number randomized; NR = not reported; SS = secret severance.

###### 

Effectiveness results including results per group

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, country                                 Treatment                                  Comparator             Duration         Outcome                 Participants analyzed, n   Results per group, mean (SD)                                                                    MD (95% CI), *P* value           Favors
  ---------------------------------------------- ------------------------------------------ ---------------------- ---------------- ----------------------- -------------------------- ----------------------------------------------------------------------------------------------- -------------------------------- -------------------------------------------------
  Acupuncture vs placebo                                                                                                                                                                                                                                                                                                

   Sunay et al,[@bib26] 2011, Turkey             Acu 2×/wk                                  Sham acu               4 wk             IELT (stopwatch)\       60                         acu: 1.10 (NR), sham acu: 0.55 (NR)[†](#tbl5fndagger){ref-type="table-fn"}\                     0.55 (NR), .001\                 Acu over sham\
                                                                                                                                    PEDT                                               acu: −4.0, sham acu: 0.0[‡](#tbl5fnddagger){ref-type="table-fn"}                                NR (NR), .001                    Acu over sham

  Acupuncture vs drug                                                                                                                                                                                                                                                                                                   

   Sunay et al,[@bib26] 2011, Turkey             Acu 2×/wk                                  Paroxetine 20 mg/d     4 wk             IELT (stopwatch)\       60                         acu: 1.10 (NR), paroxetine: 1.38 (NR)[†](#tbl5fndagger){ref-type="table-fn"}\                   −0.28 (NR), .001\                Drug over acu\
                                                                                                                                    PEDT                                               acu: −4.0, paroxetine: −5.0[‡](#tbl5fnddagger){ref-type="table-fn"}                             NR (NR), NS                      Acu vs drug NS

   Chen,[@bib27] 2009, China                     Acu daily                                  Citalopram 20 mg/d     4 wk             CIPE-5                  111                        acu: 12.56 (3.84), citalopram: 11.12 (3.77)[∗](#tbl5fnlowast){ref-type="table-fn"}              1.44 (0.02--2.86), .05           Acu over drug

  CM vs TAU                                                                                                                                                                                                                                                                                                             

   Song et al,[@bib32] 2007, China               CM (*Uighur* 2×/d)                         TAU                    15 d             IELT (questionnaire)\   68                         CM: 2.73 (1.25), TAU: 1.16 (0.58)[∗](#tbl5fnlowast){ref-type="table-fn"}\                       1.57 (1.11--2.03), \<.00001\     CM over TAU\
                                                                                                                                    CIPE-5                                             CM: 15.80 (3.60), TAU: 10.85 (3.18)[∗](#tbl5fnlowast){ref-type="table-fn"}                      4.95 (3.34--6.56), \<.00001      CM over TAU

  CM vs drug                                                                                                                                                                                                                                                                                                            

   Li and Lu,[@bib28] 2015, China                CM (*Qilin* pills 6 g 2×/d)                Sertraline 50 mg/d     4 wk             IELT (stopwatch)\       79                         CM: 3.23 (1.84), sertraline: 3.87 (2.43)[∗](#tbl5fnlowast){ref-type="table-fn"}\                −0.64 (−1.58 to 0.30), .18\      CM vs drug NS\
                                                                                                                                    PEDT                                               CM: 5.1 (1.8), sertraline: 4.9 (1.7)[∗](#tbl5fnlowast){ref-type="table-fn"}                     −0.20 (−0.97 to 0.57), .61       CM vs drug NS

   Xu et al,[@bib29] 2014, China                 CM (mycelium of *Cordyceps sinensis C4*)   Sertraline 50 mg/d     8 wk             IELT (stopwatch)\       200                        CM: 1.4 (0.7), sertraline: 3.1 (2.3)[∗](#tbl5fnlowast){ref-type="table-fn"}\                    −1.70 (−2.12 to −1.28), \<.01\   Drug over CM\
                                                                                                                                    PEDT                                               CM: 14.8 (3.5), sertraline: 11.0 (4.9)[∗](#tbl5fnlowast){ref-type="table-fn"}                   −3.8 (−5.01 to −2.59), \<.01     Drug over CM

   Sun et al,[@bib31] 2010, China                CM (*Yimusake* 1.5 g/d)                    Fluoxetine 20 mg/d     4 wk             IELT (method NR)\       76                         CM: 5.2 (0.87), fluoxetine: 5.8 (0.94)[∗](#tbl5fnlowast){ref-type="table-fn"}\                  −0.60 (−1.01 to −0.19), .004\    Drug over CM\
                                                                                                                                    satisfaction (IIEF)                                CM: 10.3 (1.26), fluoxetine: 11.2 (1.09)[∗](#tbl5fnlowast){ref-type="table-fn"}                 −0.90 (−1.43 to −0.37), .0009    Drug over CM

  CM + drug vs drug alone                                                                                                                                                                                                                                                                                               

   Li and Lu,[@bib28] 2015, China                CM (*Qilin* pills) + sertraline 50 mg/d    Sertraline 50 mg/d     4 wk             IELT (stopwatch)\       79                         CM + sertraline: 5.92 (3.11), sertraline: 3.87 (2.43)[∗](#tbl5fnlowast){ref-type="table-fn"}\   2.05 (0.83--3.27), .001\         Combined over drug\
                                                                                                                                    PEDT                                               CM + sertraline: 3.8 (1.2), sertraline: 4.9 (1.7)[∗](#tbl5fnlowast){ref-type="table-fn"}        1.10 (0.46--1.74), .0008         Combined over drug

   Sun et al,[@bib31] 2010, China                CM (*Yimusake*) + fluoxetine 20 mg/d       Fluoxetine 20 mg/d     4 wk             IELT (method NR)\       76                         CM + fluoxetine: 7.7 (0.98), fluoxetine: 5.8 (0.94)[∗](#tbl5fnlowast){ref-type="table-fn"}\     1.90 (1.47--2.33), \<.00001\     Combined over drug\
                                                                                                                                    satisfaction (IIEF)                                CM + fluoxetine: 14.2 (1.31), fluoxetine: 11.2 (1.09)[∗](#tbl5fnlowast){ref-type="table-fn"}    3.00 (2.46--3.54), \<.00001      Combined over drug

  CM + drug vs CM alone                                                                                                                                                                                                                                                                                                 

   Li and Lu,[@bib28] 2015, China                CM (*Qilin* pills) + sertraline 50 mg/d    CM (*Qilin* pills)     4 wk             IELT (stopwatch)\       80                         CM + sertraline: 5.92 (3.11), CM: 3.23 (1.84)[∗](#tbl5fnlowast){ref-type="table-fn"}\           2.69 (1.57--3.81), \<.00001\     Combined over CM\
                                                                                                                                    PEDT                                               CM + sertraline: 3.8 (1.2), CM: 5.1 (1.8)[∗](#tbl5fnlowast){ref-type="table-fn"}                1.30 (0.63--1.97), .0001         Combined over CM

   Sun et al,[@bib31] 2010, China                CM (*Yimusake*) + fluoxetine 20 mg/d       CM (*Yimusake*)        4 wk             IELT (method NR)\       76                         CM + fluoxetine: 7.7 (0.98), CM 5.2 (0.87)[∗](#tbl5fnlowast){ref-type="table-fn"}\              2.50 (2.08--2.92), \<.00001\     Combined over CM\
                                                                                                                                    satisfaction (IIEF)                                CM + fluoxetine: 14.2 (1.31), CM: 10.3 (1.26)[∗](#tbl5fnlowast){ref-type="table-fn"}            3.90 (3.32--4.48), \<.00001      Combined over CM

   Xu et al,[@bib30] 2012, China                 CM (*Yimusake*) + trazodone 50 mg/d        CM (*Yimusake*)        4 wk             IELT (method NR)        68                         CM + trazodone: 3.05 (0.60), CM: 2.97 (0.54)[∗](#tbl5fnlowast){ref-type="table-fn"}             0.08 (−0.19 to 0.35), .56        Combined vs CM NS

  Ayurvedic herbal medicine vs placebo                                                                                                                                                                                                                                                                                  

   Kulkarni and Chandola,[@bib33] 2013, India    Ayurvedic medicine + counseling            Placebo + counseling   2 mo             IELT (method NR)        50                         Ayurveda: 1.85 (0.91), placebo: 1.05 (0.82)[†](#tbl5fndagger){ref-type="table-fn"}              0.80 (0.32--1.28), .001          Ayurveda + counseling over placebo + counseling

  Topical herbal SS cream vs placebo                                                                                                                                                                                                                                                                                    

   Choi et al,[@bib34] 2000, Korea (crossover)   SS cream (0.2 g 1 h before coitus)         Placebo                5 applications   IELT (stopwatch)        106                        SS cream: 10.92 (9.78), placebo: 2.45 (2.99)[∗](#tbl5fnlowast){ref-type="table-fn"}             8.47 (6.52--10.42), \<.001       SS cream over placebo

   Choi et al,[@bib35] 1999, Korea (crossover)   SS cream (0.2 g 1 h before coitus)         Placebo                1 application    IELT (stopwatch)        50                         SS cream: 11.06 (8.27), placebo: 2.27 (2.26)[∗](#tbl5fnlowast){ref-type="table-fn"}             8.79 (6.41--11.17), \<.001       SS cream over placebo
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CIPE-5 = Chinese Index of Premature Ejaculation--5 (higher score = better); CM = Chinese medicine; IELT = intravaginal ejaculatory latency time; IIEF = International Index of Erectile Function (higher score = better); MD = mean difference; NR = not reported; NS = not significant; PEDT = Premature Ejaculation Diagnostic Tool (lower score = better; therefore, signs are reversed when calculating the MD); SS = secret severance; TAU = treatment as usual.

Mean after treatment.

Mean change from baseline.

Median change from baseline.
